310210.KQ Voronoi Co. Ltd.
- Market cap
- KRW 1.95T
- P/E
- -
- P/B
- 28.18x
- ROE
- -147.5%
- Dividend yield
- -
- Fundamental score
- 0.5/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 310210.KQ undervalued?
Graham numberThe Graham number of Voronoi Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Voronoi Co. Ltd. fundamental analysis
3 of 21 checks passedROE 0/2
Low return on equity (-147.5%), below 10%.
ROA 0/1
Return on assets (-76.3%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-30.8%) is below the industry median (1.8%).
Revenue Growth 0/2
Revenue shrank 8.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (44.9%), up to 100%.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.3 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (28.2x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Voronoi Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Voronoi Co. Ltd.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN…
Full company profileVoronoi Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Voronoi Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 301M | 6.18B | 14.8B | 9.77B | 0.00 | 0.00 | 7.51B | - |
| Gross Profit | 301M | 6.18B | 14.8B | 9.77B | - | - | 7.51B | - |
| Operating Income | -54.2B | -27.0B | -15.1B | -17.9B | -33.7B | -36.3B | -54.4B | -103B |
| EBITDA | - | - | - | -14.3B | -31.5B | -30.1B | -46.2B | -94.0B |
| Net Income | -50.0B | -23.2B | -15.1B | -19.9B | -36.8B | -32.6B | -42.7B | -102B |
| EPS | -4,086 | -1,866 | -1,215 | -1,334 | -2,168 | -1,815 | -2,374 | -5,566 |
| Balance Sheet | ||||||||
| Total Assets | 30.6B | 47.7B | 40.2B | 64.0B | 94.7B | 73.7B | 171B | 134B |
| Total Liabilities | 16.8B | 19.6B | 33.2B | 29.7B | 13.3B | 7.25B | 67.4B | 64.5B |
| Shareholders' Equity | 13.8B | 28.1B | 6.92B | 34.3B | 81.3B | 66.4B | 104B | 69.2B |
| Cash & Short-term Investments | 1.14B | 22.4B | 18.3B | 48.4B | 60.3B | 53.9B | 35.7B | 24.8B |
| Cash Flow | ||||||||
| Operating Cash Flow | -33.6B | -15.9B | -17.6B | -16.3B | -28.8B | -29.1B | -72.1B | -75.5B |
| Capital Expenditure | 5.69B | 377M | 583M | 552M | 1.08B | 1.23B | 1.68B | 7.63B |
| Free Cash Flow | - | -16.3B | -18.2B | -16.9B | -29.9B | -30.3B | -73.8B | -83.1B |
| Ratios | ||||||||
| ROE | -362.4% | -82.5% | -218.2% | -58.1% | -45.3% | -49.1% | -41.1% | -147.5% |
| ROA | -163.5% | -48.6% | -37.6% | -31.1% | -38.9% | -44.3% | -24.9% | -76.3% |
| Net Profit Margin | -16,627.5% | -375.2% | -102.1% | -203.7% | - | - | -568.5% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Voronoi Co. Ltd. dividends
Voronoi Co. Ltd. has not paid dividends in the last 7 fiscal years.
Last stock split: 1.2:1 on Sep 13, 2023.
Who owns Voronoi Co. Ltd.
- Insiders 39.10%
- Institutions 8.64%
- Public & others 52.26%
- Shares outstanding 18.4M
- Free float 10.7M
Voronoi Co. Ltd. company profile
- Company name
- Voronoi Co. Ltd.
- Ticker
- 310210.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 169
- Fiscal year end
- December
- Address
- S-18, 32, Songdogwahak-ro, Incheon, South Korea, 21984
- Phone
- 82 3 2830 4855
- Website
- voronoi.io
About Voronoi Co. Ltd.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company's products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was incorporated in 2015 and is based in Incheon, South Korea.
Voronoi Co. Ltd. management
10- Mr. Daekwon KimCEO & Director
- Mr. Sangjin WooCOO & Director · born 1976
- Mr. Jaeyoung AhnCBO, President of Voronoi USA, Inc., & Head of U.S. Operations
- Mr. Hyuntae KimCEO & Director · born 1976
- Mr. Sangjin LeeChief Financial Officer
- Mr. Hosey Hwang C.P.A.Director of Accounting
- Mr. Sunghwan Kim Ph.D.Chief Science Officer & Director of Biology Research
- Dr. Yin Zhang M.D.Chief Medical Officer
- Hwankeun ChoiExecutive Officer of Sub
- Jungbeom SonExecutive Officer · born 1976